Literature DB >> 11430633

Pharmacoutilization of antihypertensive drugs: a model of analysis.

E Degli Esposti1, A Sturani, L Degli Esposti, P L Macini, P Falasca, G Valpiani, S Buda.   

Abstract

OBJECTIVES: To identify clinical and economic indicators of pharmacoutilization of antihypertensive drugs. PATIENTS AND METHODS: 4614 subjects receiving a first prescription for amlodipine, atenolol, fosinopril, indapamide, or losartan were included in the study. All prescriptions filled during the study period from January 1, 1997 to December 31, 1998 were considered. A retrospective analysis was carried out on information recorded in the drug database. The percentage of patients continuing, discontinuing, and switching the initial treatment, duration of treatment, and doses used were calculated together with total costs.
RESULTS: A large proportion of patients (65.1%) discontinued the treatment. From the analysis of the mean daily dose taken by patients who continued the treatment, it was found that many subjects took a drug dosage which was below the therapeutic dose range, whereas the administration of doses above the therapeutic range occurred only occasionally. Continuation of treatment accounted for 48.1% of total costs, switching accounted for 20.8%, and discontinuation represented 31.1% of total expenditures.
CONCLUSIONS: With adequate markers, helpful data can be collected for monitoring the quality of antihypertensive drug prescriptions and the rational usage of resources in the general practice setting.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11430633

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  13 in total

1.  Frequency of cardiovascular events in patients treated with anti hypertensive agents: A cohort study based on claims data generated by primary care practice.

Authors:  Pierluigi Russo; Alessandro Capone; Alessandra Sturani; Ezio Degli Esposti
Journal:  Curr Ther Res Clin Exp       Date:  2004-09

Review 2.  Compliance and persistence with newer antihypertensive agents.

Authors:  William C Gerth
Journal:  Curr Hypertens Rep       Date:  2002-12       Impact factor: 5.369

3.  Compliance with therapy in hypertensive patients.

Authors:  Alfonso Lagi; Antonio Rossi; Maria Teresa Passaleva; Alessandro Cartei; Simone Cencetti
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

Review 4.  Pharmacoeconomic burden of undertreating hypertension.

Authors:  Luca Degli Esposti; Giorgia Valpiani
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

5.  Prevalence, treatment, and control of hypertension in primary care: gaps, trends, and opportunities.

Authors:  Robert J Petrella; Elizabeth P Merikle; Jared Jones
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-01       Impact factor: 3.738

6.  Treatment for newly diagnosed hypertension: patterns of prescribing and antihypertensive effectiveness in the UK.

Authors:  Tom Walley; Andy K Duggan; Alan R Haycox; Christie J Niziol
Journal:  J R Soc Med       Date:  2003-11       Impact factor: 18.000

7.  Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies.

Authors:  Luca Degli Esposti; Mirko Di Martino; Stefania Saragoni; Andrea Sgreccia; Alessandro Capone; Stefano Buda; Ezio Degli Esposti
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-02       Impact factor: 3.738

8.  The managed hypertensive: the costs of blood pressure control in a Nigerian town.

Authors:  Olayinka Stephen Ilesanmi; Olusimbo Kehinde Ige; Akindele Olupelumi Adebiyi
Journal:  Pan Afr Med J       Date:  2012-08-06

9.  Drug adherence behavior among hypertensive out-patients at a tertiary health institution in Manicaland province, Zimbabwe, 2011.

Authors:  Fadzai Nn Mukora-Mutseyekwa; Elizabeth M Chadambuka
Journal:  Patient Prefer Adherence       Date:  2013-01-17       Impact factor: 2.711

Review 10.  Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review.

Authors:  Peter Bramlage; Joerg Hasford
Journal:  Cardiovasc Diabetol       Date:  2009-03-27       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.